NMN dosage

Protocol

1. 1

   Measure the dose

   Typical NMN dose is 250 mg (250 mg/day is the most-studied trial dose (Yoshino 2021, Igarashi 2022); 500 to 1000 mg/day is common in consumer marketing without proportionate trial support). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 1x daily, often morning. Half-life of 4 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No cycling required; longest trials are 12 months at 250 mg/day

   Open tool →
4. 4

   Monitor for side effects

   Watch for: mild GI upset (rare); occasional headache; flushing (rare). Stop or reduce dose if tolerability breaks down.

Why this dose

Direct precursor in the NAD+ salvage pathway; converted to NAD+ by NMNAT enzymes in essentially every tissue. Raised NAD+ supports sirtuin and PARP enzyme activity.

The typical dose (250 mg) reflects 250 mg/day is the most-studied trial dose (Yoshino 2021, Igarashi 2022); 500 to 1000 mg/day is common in consumer marketing without proportionate trial support. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

NMN is administered via the oral or sublingual routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted. Sublingual dosing requires holding the dose under the tongue for 60 to 90 seconds before swallowing to maximize mucosal absorption.

Onset of action runs around 1 hour after administration. Peak effect lands near 3 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma NMN metabolites peak 2 to 4 hours post-dose; plasma NAD+ rise persists 12 to 24 hours after single dose

Cycling and tolerance

No cycling required; longest trials are 12 months at 250 mg/day

Effects to expect at typical dose

• Plasma NAD+ rises 30-90% at 250-1000 mg/day across human PK studies
• Tissue NAD+ rise is inconsistent across human trials (Yoshino 2021, Igarashi 2022)
• No human trials measure hard endpoints (mortality, CV events, cancer); evidence is biomarker-only
• Most trials cluster at 250-500 mg/day; dose-response above 250 mg/day is poorly characterized
• FDA position contested; widely sold as supplement but with regulatory uncertainty
• Marketing claims for fertility and longevity outrun the human trial evidence substantially

Side effects and interactions

Common side effects

• mild GI upset (rare)
• occasional headache
• flushing (rare)

Notable interactions

• chemotherapy agents (moderate): theoretical concern about supporting cancer cell proliferation; coordinate with oncology team
• metformin (minor): no clinically significant interaction documented; both modulate metabolism through different mechanisms
• CD38 inhibitors (minor): would amplify NMN-induced NAD+ rise; not clinically relevant for most users

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full NMN profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Not scheduled

Pregnancy

Insufficient data; precautionary avoidance

Legal status

Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia

Do not use if

• pregnancy and lactation (precautionary, no data)
• active cancer (theoretical concern, not evidence-based)

Related research